Yeon Hee Park, MD, PhD, on Metastatic Breast Cancer: Updated Survival Results of the Young-PEARL Study
2024 ASCO Annual Meeting
Yeon Hee Park, MD, PhD, of South Korea’s Samsung Medical Center and Sungkyunkwan University, discusses phase II findings on palbociclib plus exemestane with a GnRH agonist vs capecitabine in premenopausal patients with hormone receptor–positive, HER2-negative metastatic breast cancer (LBA1002).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
YoungPEARL study is a prospective randomized phase 2 study to compare palbociclib plus exemestane plus GnRH agonist versus capecitabine for premenopausal HR-positive HER2-negative metastatic breast cancers. Actually, this clinical trial was published and presented in 2019. According to that trial research, palbociclib plus exemestane plus GnRH antagonist showed a superior PFS compared to the capecitabine. Their median PFS was 20.1 months versus capecitabine, 14.4 months. This kind of real big research contributed to expansion of palbociclib plus AI label to include premenopausal population.
So now, here we reported updated overall survival research. Data cutoff is February 29th, 2024 with median follow-up duration of 54 months. So we follow up the updated PFS research to show the consistent superior PFS showed in palbociclib arm. Median PFS was 19.5 months versus 14 months of PFS shown in capecitabine arm. Hazard ratio in people was strongly enough to consider it's a big impact in terms of PFS.
And now, we show the overall survival research. There is no big difference between the two arm. Palbociclib arm showed the 54.7 months of PFS, and then capecitabine arm showed a remarkable PFS of 57.8 months. They did not show any difference, but it's 54 months of longer follow-up duration. Palbociclib arm showed a pretty consistent, longer overall survival of 54.8 months. So it's a really... Extended overall survival was shown in palbociclib arm. But palbociclib superior PFS did not lead to the overall survival benefit compare capecitabine arm. But capecitabine arm showed... Multivariate analysis showed the post-treatment CDK4/6 inhibitor was identified as a independent favorable factor for overall survival with statistical significance. So maybe post CDK inhibitor treatment contributed to extended overall survival in palbociclib arm.
Related Videos
The ASCO Post Staff
Andrew Srisuwananukorn, MD, of The Ohio State University, and Alexander T. Pearson, MD, PhD, of the University of Chicago, discuss the use of artificial intelligence (AI) in the clinic, its potential benefits in diagnosis and treatment, resources available to help physicians learn more about AI, and what’s coming for the next generation of medical school students.
The ASCO Post Staff
Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, PhD, of Institut Gustave Roussy and the University of Paris-Saclay, discuss a second interim analysis of the health-related quality of life and pain outcomes in the PSMAfore study (Abstract 5003).
The ASCO Post Staff
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for patients with high-risk relapsed or refractory chronic lymphocytic leukemia. It offers delayed disease progression and favorable survival and response, compared with alternative BTK inhibitors (Abstract 7048).
The ASCO Post Staff
Omid Hamid, MD, of The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, discusses updated data on IMC-F106C, a novel bispecific protein that, in a phase I safety and efficacy study, exhibited clinical activity in patients with unresectable or metastatic cutaneous melanoma who were pretreated with immune checkpoint inhibitors. A phase III trial of IMC-F106C with nivolumab in the first-line setting of metastatic disease has been initiated (NCT06112314; Abstract 9507).
The ASCO Post Staff
Peter Riedell, MD, of The University of Chicago, discusses phase III results on the use of tucidinostat plus R-CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) with double expression of MYC and BCL2. The regimen appeared to improve event-free survival and complete response rates vs R-CHOP in the front-line setting. As this is an interim analysis, longer-term follow-up will be needed to better understand its impact, says Dr. Riedell.